1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (ML 1024), a new hypolipemic agent.
1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (ML 1024) was tested on acute and chronic toxicity, on teratogenesis and fetotoxicity, on blood pressure and blood flow behaviour, on hypolipemic activity and general pharmacological behaviour in a screening test using 54 parameters. Results warrant further investigation of the potential therapeutic application of ML 1024 in humans based on its superiority to the well-known antilipemic clofibrate (CPIB).
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D005260:Female; D006949:Hyperlipidemias / Q000188:drug therapy; D008297:Male; D051379:Mice; D011247:Pregnancy; D011422:Propionates / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D013552:Swine; D013806:Theophylline / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity
D011422:Propionates; D013806:Theophylline